Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/183446

Lähdeviite

de Mello , V D , Paananen , J , Lindstrom , J , Lankinen , M A , Shi , L , Kuusisto , J , Pihlajamaki , J , Auriola , S , Lehtonen , M , Rolandsson , O , Bergdahl , I A , Nordin , E , Ilanne-Parikka , P , Keinanen-Kiukaanniemi , S , Landberg , R , Eriksson , J G , Tuomilehto , J , Hanhineva , K & Uusitupa , M 2017 , ' Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study ' , Scientific Reports , vol. 7 , 46337 . https://doi.org/10.1038/srep46337

Julkaisun nimi: Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study
Tekijä: de Mello, Vanessa D.; Paananen, Jussi; Lindstrom, Jaana; Lankinen, Maria A.; Shi, Lin; Kuusisto, Johanna; Pihlajamaki, Jussi; Auriola, Seppo; Lehtonen, Marko; Rolandsson, Olov; Bergdahl, Ingvar A.; Nordin, Elise; Ilanne-Parikka, Pirjo; Keinanen-Kiukaanniemi, Sirkka; Landberg, Rikard; Eriksson, Johan G.; Tuomilehto, Jaakko; Hanhineva, Kati; Uusitupa, Matti
Tekijän organisaatio: Clinicum
Johan Eriksson / Principal Investigator
Department of General Practice and Primary Health Care
Päiväys: 2017-04-11
Kieli: eng
Sivumäärä: 12
Kuuluu julkaisusarjaan: Scientific Reports
ISSN: 2045-2322
DOI-tunniste: https://doi.org/10.1038/srep46337
URI: http://hdl.handle.net/10138/183446
Tiivistelmä: Wide-scale profiling technologies including metabolomics broaden the possibility of novel discoveries related to the pathogenesis of type 2 diabetes (T2D). By applying non-targeted metabolomics approach, we investigated here whether serum metabolite profile predicts T2D in a well-characterized study population with impaired glucose tolerance by examining two groups of individuals who took part in the Finnish Diabetes Prevention Study (DPS); those who either early developed T2D (n = 96) or did not convert to T2D within the 15-year follow-up (n = 104). Several novel metabolites were associated with lower likelihood of developing T2D, including indole and lipid related metabolites. Higher indolepropionic acid was associated with reduced likelihood of T2D in the DPS. Interestingly, in those who remained free of T2D, indolepropionic acid and various lipid species were associated with better insulin secretion and sensitivity, respectively. Furthermore, these metabolites were negatively correlated with low-grade inflammation. We replicated the association between indolepropionic acid and T2D risk in one Finnish and one Swedish population. We suggest that indolepropionic acid, a gut microbiota-produced metabolite, is a potential biomarker for the development of T2D that may mediate its protective effect by preservation of alpha-cell function. Novel lipid metabolites associated with T2D may exert their effects partly through enhancing insulin sensitivity.
Avainsanat: IMPAIRED GLUCOSE-TOLERANCE
INSULIN SENSITIVITY
INDOLE-3-PROPIONIC ACID
MASS-SPECTROMETRY
INDOLIC COMPOUNDS
GUT MICROBIOTA
AMINO-ACIDS
FATTY-ACIDS
LIFE-STYLE
BIOMARKERS
3111 Biomedicine
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: unspecified
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
Indolepropionic_acid.pdf 853.3KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot